Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

Abstract Background Cisplatin is the most commonly used chemotherapeutic agent in the treatment of patients with metastatic and/or recurrent urothelial cancer. However, the effectiveness of these treatments is severely limited due to the development of cisplatin resistance. Cancer stem cells have be...

Full description

Bibliographic Details
Main Authors: Masayuki Hagiwara, Eiji Kikuchi, Nobuyuki Tanaka, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Cancer
Subjects:
cisplatin
chemoresistance
CD44
variant isoform
xCT
Online Access:http://link.springer.com/article/10.1186/s12885-018-3988-3

Internet

http://link.springer.com/article/10.1186/s12885-018-3988-3

Similar Items